Literature DB >> 16328467

Carbohydrate-binding specificities of mouse ficolin A, a splicing variant of ficolin A and ficolin B and their complex formation with MASP-2 and sMAP.

Y Endo1, N Nakazawa, Y Liu, D Iwaki, M Takahashi, T Fujita, M Nakata, M Matsushita.   

Abstract

Ficolins are a group of proteins mainly consisting of collagen-like and fibrinogen-like domains and are thought to play a role in innate immunity via their carbohydrate-binding activities. Two types of ficolins have been identified in mice, ficolin A, and ficolin B. However, their structure and function are not fully understood. In this study, we isolated the cDNA encoding a novel variant of ficolin A having a shorter collagen-like domain and a longer gap sequence, which was generated from the ficolin A gene by alternative splicing. We delineated the structure and function of mouse ficolins, including this splicing variant, by preparing the respective recombinants. Recombinant ficolin A, its splicing variant, and ficolin B showed multimeric structures and revealed binding to both N-acetylglucosamine and N-acetylgalactosamine. Interestingly, ficolin B specifically recognized sialic acid residues. Ficolin A and its variant, but not ficolin B, bound to mannose-binding lectin (MBL)-associated serine protease-2 (Masp-2) and small MBL-associated protein (smap), and the resulting complexes showed a potent complement activating capacity. In addition, smap competed with Masp-2 in association with ficolin A and its variant, and inhibited the complement activation by the ficolin A (or ficolin A variant)/MASP-2 complex, indicating its regulatory role in the lectin pathway. These results suggest that ficolin A and its variant function as recognition molecules of the lectin pathway, and ficolin B plays a distinct role through its unique carbohydrate-binding specificity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328467     DOI: 10.1007/s00251-005-0058-1

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  35 in total

1.  Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci.

Authors:  Youko Aoyagi; Elisabeth E Adderson; Jin G Min; Misao Matsushita; Teizo Fujita; Shinji Takahashi; Yoshiyuki Okuwaki; John F Bohnsack
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

2.  Cloning and characterization of the human lectin P35 gene and its related gene.

Authors:  Y Endo; Y Sato; M Matsushita; T Fujita
Journal:  Genomics       Date:  1996-09-15       Impact factor: 5.736

3.  A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin.

Authors:  M Matsushita; Y Endo; S Taira; Y Sato; T Fujita; N Ichikawa; M Nakata; T Mizuochi
Journal:  J Biol Chem       Date:  1996-02-02       Impact factor: 5.157

4.  Identification and functional characterization of a human GalNAc [alpha]2,6-sialyltransferase with altered expression in breast cancer.

Authors:  Georgia Sotiropoulou; Mari Kono; Anthony Anisowicz; Goran Stenman; Shuichi Tsuji; Ruth Sager
Journal:  Mol Med       Date:  2002-01       Impact factor: 6.354

5.  MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway.

Authors:  M R Dahl; S Thiel; M Matsushita; T Fujita; A C Willis; T Christensen; T Vorup-Jensen; J C Jensenius
Journal:  Immunity       Date:  2001-07       Impact factor: 31.745

6.  Purification of transforming growth factor-beta 1 binding proteins from porcine uterus membranes.

Authors:  H Ichijo; L Rönnstrand; K Miyagawa; H Ohashi; C H Heldin; K Miyazono
Journal:  J Biol Chem       Date:  1991-11-25       Impact factor: 5.157

7.  Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family.

Authors:  R Sugimoto; Y Yae; M Akaiwa; S Kitajima; Y Shibata; H Sato; J Hirata; K Okochi; K Izuhara; N Hamasaki
Journal:  J Biol Chem       Date:  1998-08-14       Impact factor: 5.157

8.  Oligomeric structure and tissue distribution of ficolins from mouse, pig and human.

Authors:  T Ohashi; H P Erickson
Journal:  Arch Biochem Biophys       Date:  1998-12-15       Impact factor: 4.013

9.  Human ficolin: cDNA cloning, demonstration of peripheral blood leucocytes as the major site of synthesis and assignment of the gene to chromosome 9.

Authors:  J Lu; P N Tay; O L Kon; K B Reid
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

Review 10.  Evolution of the lectin-complement pathway and its role in innate immunity.

Authors:  Teizo Fujita
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

View more
  16 in total

1.  Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin.

Authors:  Wei-Chuan Chang; Kevan L Hartshorn; Mitchell R White; Patience Moyo; Ian C Michelow; Henry Koziel; Bernard T Kinane; Emmett V Schmidt; Teizo Fujita; Kazue Takahashi
Journal:  Biochem Pharmacol       Date:  2010-10-28       Impact factor: 5.858

2.  Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis.

Authors:  Nirmal K Banda; Minoru Takahashi; Brandt Levitt; Magdalena Glogowska; Jessica Nicholas; Kazue Takahashi; Gregory L Stahl; Teizo Fujita; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

3.  Roles of adipocytes and fibroblasts in activation of the alternative pathway of complement in inflammatory arthritis in mice.

Authors:  William P Arend; Gaurav Mehta; Alexandra H Antonioli; Minoru Takahashi; Kazue Takahashi; Gregory L Stahl; V Michael Holers; Nirmal K Banda
Journal:  J Immunol       Date:  2013-05-06       Impact factor: 5.422

4.  Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement.

Authors:  Nirmal K Banda; Minoru Takahashi; Kazue Takahashi; Gregory L Stahl; Stephanie Hyatt; Magdalena Glogowska; Timothy A Wiles; Yuichi Endo; Teizo Fujita; V Michael Holers; William P Arend
Journal:  Mol Immunol       Date:  2011-09-23       Impact factor: 4.407

Review 5.  Protection of host cells by complement regulators.

Authors:  Christoph Q Schmidt; John D Lambris; Daniel Ricklin
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

6.  Deconstructing the Lectin Pathway in the Pathogenesis of Experimental Inflammatory Arthritis: Essential Role of the Lectin Ficolin B and Mannose-Binding Protein-Associated Serine Protease 2.

Authors:  Nirmal K Banda; Sumitra Acharya; Robert I Scheinman; Gaurav Mehta; Minoru Takahashi; Yuichi Endo; Wuding Zhou; Conrad A Farrar; Steven H Sacks; Teizo Fujita; Hideharu Sekine; V Michael Holers
Journal:  J Immunol       Date:  2017-07-24       Impact factor: 5.422

7.  Role of ficolin-A and lectin complement pathway in the innate defense against pathogenic Aspergillus species.

Authors:  Stefan Bidula; Hany Kenawy; Youssif M Ali; Darren Sexton; Wilhelm J Schwaeble; Silke Schelenz
Journal:  Infect Immun       Date:  2013-03-11       Impact factor: 3.441

8.  Carbohydrate recognition and complement activation by rat ficolin-B.

Authors:  Umakhanth Venkatraman Girija; Daniel A Mitchell; Silke Roscher; Russell Wallis
Journal:  Eur J Immunol       Date:  2010-12-03       Impact factor: 5.532

9.  Mouse ficolin B has an ability to form complexes with mannose-binding lectin-associated serine proteases and activate complement through the lectin pathway.

Authors:  Yuichi Endo; Daisuke Iwaki; Yumi Ishida; Minoru Takahashi; Misao Matsushita; Teizo Fujita
Journal:  J Biomed Biotechnol       Date:  2012-02-29

10.  Localization and characterization of the mannose-binding lectin (MBL)-associated-serine protease-2 binding site in rat ficolin-A: equivalent binding sites within the collagenous domains of MBLs and ficolins.

Authors:  Umakhanth Venkatraman Girija; Alister W Dodds; Silke Roscher; Kenneth B M Reid; Russell Wallis
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.